Edward Elgar Publishing eBooks
January 20, 2026
Muireann Quigley, Matt Hayler
In this chapter, we consider the therapeutic potential of psychedelics, such as psilocybin and midomafetamine (MDMA), as a novel response to deepening mental health crises. In particular, we examine this in the context of restrictive drug control systems across Europe (including the United Kingdom). Whilst promising results from several clinical studies have fed into and helped to perpetuate a...
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
January 20, 2026
Ke Xia, Tianming Gao
Depression is a complex and globally prevalent mental disorder, for which conventional antidepressant medications face limitations such as delayed onset and insufficient efficacy. Classic psychedelics, most notably psilocybin, have recently emerged as promising candidates for treatment of depression and demonstrated rapid, robust, and sustained antidepressant effects in controlled clinical...
Addiction
January 20, 2026
Tibor Markus Brunt
2 citations
Revived interest in psychedelic-assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti-addictive potential. Evidence from observational, open-label, and limited randomized placebo-controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in opioid and cocaine-dependent individuals, primarily...
Veterinary sciences
January 19, 2026
Elisa Hernández-Álvarez, Cristina Canino-Quijada, Sira Roiz et al.
Shelter environments frequently expose dogs to chronic stress and anxiety, which can compromise their welfare and reduce their chances of adoption. Recent interest in psychedelic-assisted approaches has suggested potential therapeutic applications in veterinary behavioral medicine, although empirical evidence remains scarce. This study aimed to evaluate the combined effects of low-dose...
Journal of Affective Disorders
January 19, 2026
Maria Garcia Garcia, Dahbia Belahda, Carine Graux et al.
Responders were distinguished by narratives of inner dialogue and adaptive coping, while non-responders emphasized sensory and affective descriptions and suppressive coping. Inner dialogue may constitute a distinct therapeutic mechanism, highlighting the importance of preparation and integration in psilocybin-assisted psychotherapy.
Neuropsychopharmacology
January 16, 2026
Philip D. Harvey, Charles B. Nemeroff
2 citations
Interest in psychedelic therapies is booming, with hundreds of studies in process. Despite the interest, there are no approved psychedelic treatments for any psychiatric condition. Further, the one large-scale development program using MDMA that reached the FDA was disapproved by the agency for reasons that could apply to clinical trials for classical psychedelics. We review the definitions of...
European Neuropsychopharmacology
January 16, 2026
Damian Swieczkowski, Aleksander Kwaśny, Krzysztof Sadko et al.
1 citation
Psilocybin-assisted therapies are increasingly studied for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD), and methodological rigor requires both pharmacological evaluation and consistent reporting of non-pharmacological variables that influence therapeutic outcomes. To address this need, the ReSPCT (Reporting of Setting in Psychedelic Clinical Trials) guidelines were...
Journal of Addiction Medicine
January 15, 2026
Dale Terasaki, Nathan Sackett, Andrew A. Monte
The psychedelic substance, ibogaine, has garnered growing interest among policymakers, researchers, and the public in its potential use for opioid use disorder (OUD). Many states are allocating significant funds to investigate it further. However, some proponents of ibogaine are framing it in opposition to (versus complementary to) standard, mortality-reducing medications for OUD (MOUD)....
bioRxiv Preprint Server
January 14, 2026
Muad Y. Abd El Hay, Ana Cukić, Marieke Schölvinck et al.
preprint
Psychedelic substances show promise for treating psychiatric disorders including depression, anxiety, and PTSD, but the neurobiological mechanisms underlying their therapeutic effects remain poorly understood. Preclinical findings have so far been inconsistent, limiting mechanistic insights. We argue this translational gap is exacerbated by systematic disconnects between conditions thought to...
January 13, 2026
David Rosen, Frederick S. Barrett, Albert Garcia‐romeu et al.
preprint
Personally meaningful music can evoke vivid emotions and autobiographical memories, reconnecting listeners with their personal past. Whether the autobiographical salience of music, as distinct from familiarity, modulates its effects on an individual’s state of consciousness has not been systematically tested. We compared autobiographically salient (AS) music with a standardized therapeutic...